Home » Stocks » Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (MIST)

Stock Price: $3.72 USD -0.05 (-1.33%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 91.61M
Revenue (ttm) n/a
Net Income (ttm) -61.12M
Shares Out 24.63M
EPS (ttm) -2.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $3.72
Previous Close $3.77
Change ($) -0.05
Change (%) -1.33%
Day's Open 3.78
Day's Range 3.66 - 3.91
Day's Volume 276,521
52-Week Range 1.69 - 25.41

More Stats

Market Cap 91.61M
Enterprise Value n/a
Earnings Date (est) Aug 18, 2020
Ex-Dividend Date n/a
Shares Outstanding 24.63M
Float 8.21M
EPS (basic) -2.86
EPS (diluted) -2.81
FCF / Share -2.24
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.21M
Short Ratio 0.73
Short % of Float 7.73%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.03
Revenue n/a
Operating Income -63.71M
Net Income -61.12M
Free Cash Flow -54.91M
Net Cash 101.46M
Net Cash / Share 4.12
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -43.58%
ROE -70.67%
ROIC -436.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 1
Overweight 0
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

(7.53% upside)
Current: 3.72
Target: 4.00
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-57.88-23.82-8.27
Net Income-55.23-23.19-8.09
Shares Outstanding15.780.320.24
Earnings Per Share-3.50-72.63-34.15
Operating Cash Flow-51.15-21.05-8.05
Capital Expenditures-0.41-0.01-0.04
Free Cash Flow-51.57-21.05-8.09
Cash & Equivalents12085.9826.91
Total Debt0.51--
Net Cash / Debt11985.9826.91
Book Value115-55.21-33.12
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Milestone Pharmaceuticals Inc.
Country Canada
Employees 30
CEO Joseph G. Oliveto

Stock Information

Ticker Symbol MIST
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MIST


Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes etripamil for the treatment of cardiovascular indications. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for the treatment of atrial fibrillation, angina, and other cardiovascular indications. The company was founded in 2003 and is headquartered in Montréal, Canada.